Abstract 985P
Background
Atezo+bev is a standard of care 1L treatment for uHCC. Currently, there is no evidence to guide treatment decision-making after discontinuation of 1L atezo+bev. Therefore, we aimed to describe the real-world characteristics and outcomes in pts with uHCC who initiated 2L therapy after receiving 1L atezo+bev vs those who did not.
Methods
Oncologists from a US nationally representative network extracted electronic medical chart data for pts with uHCC who received 1L atezo+bev between June 1, 2020 and March 6, 2023. Pts were stratified into two groups based on whether they started 2L therapy within 8 weeks of 1L atezo+bev discontinuation. Pt demographic and clinical characteristics, duration of 1L treatment (DOT), and overall survival (OS) were assessed.
Results
We identified 484 eligible pts (median age, 66 years; 64.9% male; 62.6% White). At baseline, most had good performance status (ECOG PS 0–1, 79.5%) and liver function (Child-Pugh [CP]-A, 81.4%). A higher proportion of pts in the 2L (n=141) vs no 2L (n=40) cohort were White (69.5% vs 52.5%), non-Hispanic (78.0% vs 60.0%), and had Medicare/Medicaid insurance (72.3% vs 45.0%). Between 1L and 2L initiation, liver function deteriorated (CP-A, 74.5% to 52.5%) as did performance status (ECOG PS ≥2: 8.5% to 45.3%). Pts who did not initiate 2L therapy had worse performance status (ECOG PS ≥2, 52.5% vs 8.5%) and liver dysfunction (CP-B or C, 40.0% vs 25.5%). Although median 1L DOT was similar between the 2L and no 2L cohorts (6.9 vs 7.8 months), median OS from 1L initiation was nearly twice as long among 2L (26.0 months [95% CI 21.3, 27.2]) vs no 2L (14.3 months [95% CI 10.2, 24.8]) cohort pts.
Conclusions
This study provides real-world data for sequential therapy in uHCC following atezo+bev. The findings showed differences between pts initiating 2L therapy and those who did not, highlighting the need for better pt selection at the start of 1L atezo+bev and the potential benefit of timely switching from 1L atezo+bev to subsequent therapies.
Clinical trial identification
Editorial acknowledgement
Editorial assistance in the preparation of this abstract was provided by OPEN Health Scientific Communications, London, UK, with financial support from Bayer.
Legal entity responsible for the study
The authors.
Funding
Bayer.
Disclosure
A. Singal: Financial Interests, Personal, Speaker, Consultant, Advisor: Bayer, Eisai, Genentech, BMS, Exelixis, AstraZeneca, Wako Diagnostics, Exact Sciences, Roche, Glycotest, GRAIL, TARGET PharmaSolutions. K. Ozgurdal, Z. Vassilev, F. Pisa, X. Pan: Financial Interests, Personal, Full or part-time Employment: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18